Onset and duration of visual acuity improvement after dexamethasone intravitreal implant in eyes with macular edema due to retinal vein occlusion

Retina

Volumn 34, Issue 9, 2014, Pages 1743-1749

  Kuppermann, Baruch D ^a   Haller, Julia A ^b   Bandello, Francesco ^c   Loewenstein, Anat ^d   Jiao, Jenny ^e   Li, Xiao Yan ^e   Whitcup, Scott M ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b WILLS EYE HOSPITAL   (United States)

^c UNIVERSITY OF UDINE   (Italy)

^d TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^e ALLERGAN INC   (United States)

Author keywords

Corticosteroids; Duration of effect; Intravitreal injections; Macular edema; Onset of effect; Retinal vein occlusion; Therapy; Visual acuity

Indexed keywords

DEXAMETHASONE; DRUG IMPLANT; GLUCOCORTICOID;

ADULT; AGED; ARTICLE; BRANCH RETINAL VEIN OCCLUSION; CENTRAL RETINA VEIN OCCLUSION; CONTROLLED STUDY; DRUG IMPLANT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; RANDOMIZED CONTROLLED TRIAL; RETINA MACULA EDEMA; TREATMENT OUTCOME; VISUAL ACUITY; CLINICAL TRIAL; COMPLICATION; MACULAR EDEMA; MIDDLE AGED; PATHOPHYSIOLOGY; PHASE 3 CLINICAL TRIAL; PHYSIOLOGY; RETINAL VEIN OCCLUSION; TIME; VERY ELDERLY; VITREOUS BODY;

ADULT; AGED; AGED, 80 AND OVER; DEXAMETHASONE; DRUG IMPLANTS; FEMALE; GLUCOCORTICOIDS; HUMANS; MACULAR EDEMA; MALE; MIDDLE AGED; RETINAL VEIN OCCLUSION; TIME FACTORS; TREATMENT OUTCOME; VISUAL ACUITY; VITREOUS BODY;

EID: 84906938815     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0000000000000167     Document Type: Article

References (23)

1. Mohamed Q, McIntosh RL, Saw SM, Wong TY. Interventions for central retinal vein occlusion: an evidence-based systematic review. Ophthalmology 2007;114:507-519. 524.
2. Rehak J, Rehak M. Branch retinal vein occlusion: pathogenesis, visual prognosis, and treatment modalities. Curr Eye Res 2008;33:111-131.
3. Rehak M, Wiedemann P. Retinal vein thrombosis: pathogenesis and management. J Thromb Haemost 2010;8:1886-1894.
4. Rogers S, McIntosh RL, Cheung N, et al. The prevalence of retinal vein occlusion: pooled data from population studies from the United States, Europe, Asia, and Australia. Ophthalmology 2010;117:313.e1-319.e1.
5. Yeh WS, Haller JA, Lanzetta P, et al. Effect of the duration of macular edema on clinical outcomes in retinal vein occlusion treated with dexamethasone intravitreal implant. Ophthalmology 2012;119:1190-1198.
6. Daien V, Navarre S, Fesler P, et al. Visual acuity outcome and predictive factors after bevacizumab for central retinal vein occlusion. Eur J Ophthalmol 2012;22:1013-1018.
7. Campochiaro PA. Anti-vascular endothelial growth factor treatment for retinal vein occlusions. Ophthalmologica 2012; 227(suppl 1):30-35.
8. Ip MS, Scott IU, VanVeldhuisen PC, et al; SCORE Study Research Group. A randomized trial comparing the efficacy and safety of intravitreal triamcinolone with observation to treat vision loss associated with macular edema secondary to central retinal vein occlusion: the Standard Care vs Corticosteroid for Retinal Vein Occlusion (SCORE) study report 5. Arch Ophthalmol 2009;127:1101-1114.
9. Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. Curr Opin Ophthalmol 2012;23:175-181.
10. Campochiaro PA, Heier JS, Feiner L, et al; BRAVO Investigators. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1102.e1-1112.e1.
11. Brown DM, Campochiaro PA, Singh RP, et al; CRUISE Investigators. Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study. Ophthalmology 2010;117:1124.e1-1133.e1.
12. Demir M, Oba E, Gulkilik G, et al. Intravitreal bevacizumab for macular edema due to branch retinal vein occlusion: 12-month results. Clin Ophthalmol 2011;5:745-749.
13. Karagiannis DA, Karampelas MD, Soumplis VM, et al. Recurrence of macular edema in retinal vein occlusions after treatment with intravitreal ranibizumab (Lucentis). Can J Ophthalmol 2011;46:486-490.
14. Chang LK, Spaide RF, Klancnik JM, et al. Longer-term outcomes of a prospective study of intravitreal ranibizumab as a treatment for decreased visual acuity secondary to central retinal vein occlusion. Retina 2011;31:821-828.
15. Costa RA, Jorge R, Calucci D, et al. Intravitreal bevacizumab (avastin) for central and hemicentral retinal vein occlusions: IBeVO study. Retina 2007;27:141-149.
16. Herrero-Vanrell R, Cardillo JA, Kuppermann BD. Clinical applications of the sustained-release dexamethasone implant for treatment of macular edema. Clin Ophthalmol 2011;5: 139-146.
17. Haller JA, Bandello F, Belfort R Jr, et al; OZURDEX GENEVA Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117: 1134.e3-1146.e3.
18. Haller JA, Bandello F, Belfort R Jr, et al; Ozurdex GENEVA Study Group. Dexamethasone intravitreal implant in patients with macular edema related to branch or central retinal vein occlusion twelve-month study results. Ophthalmology 2011; 118:2453-2460.
19. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985;103:1796-1806.
20. Chang-Lin JE, Attar M, Acheampong AA, et al. Pharmacokinetics and pharmacodynamics of a sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2011;52: 80-86.
21. Miyamoto N, Iossifov D, Metge F, Behar-Cohen F. Early effects of intravitreal triamcinolone on macular edema: mechanistic implication. Ophthalmology 2006;113:2048-2053.
22. Querques L, Querques G, Lattanzio R, et al. Repeated intravitreal dexamethasone implant (Ozurdex) for retinal vein occlusion. Ophthalmologica 2013;229:21-25.
23. Capone AJ, Singer MA, Dodwell DG, et al. Efficacy and safety of two or more dexamethasone intravitreal implant injections for treatment of macular edema related to retinal vein occlusion (SHASTA study). Retina 2014;34:342-351.